<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01748448</url>
  </required_header>
  <id_info>
    <org_study_id>2012LRDVDCM</org_study_id>
    <secondary_id>2012-002125-30</secondary_id>
    <nct_id>NCT01748448</nct_id>
  </id_info>
  <brief_title>Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome</brief_title>
  <acronym>ViDMe</acronym>
  <official_title>Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KU Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess whether vitamin D supplementation after surgery of a first cutaneous malignant&#xD;
      melanoma protects against relapse of the disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess whether vitamin D supplementation, in the follow up period after diagnosis and&#xD;
      surgery of a first cutaneous malignant melanoma, has a protective effect on relapse of&#xD;
      cutaneous malignant melanoma and whether this protective effect correlates with vitamin D&#xD;
      levels in serum and vitamin D receptor (VDR) immunoreactivity in the primary tumor.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse free survival</measure>
    <time_frame>study duration maximum 3,5 years</time_frame>
    <description>Disease free survival will be the primary endpoint of this phase III trial. Patients are enrolled during a recruitment phase of three years maximum. Study duration for one patient is maximum 3,5 years or until relapse occurs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Melanoma subtype, as assessed clinically and histologically</measure>
    <time_frame>study duration maximum 3,5 years</time_frame>
    <description>Vitamin D levels at diagnosis will be correlated with melanoma subtype, as assessed clinically and histologically.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Melanoma site, as clinically recorded</measure>
    <time_frame>study duration maximum 3,5 years</time_frame>
    <description>Vitamin D levels at diagnosis will be correlated with melanoma site, as clinically recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>25(OH)D3 serum levels</measure>
    <time_frame>study duration maximum 3,5 years</time_frame>
    <description>25(OH)D3 serum levels will be recorded at diagnosis and at 6 months intervals up to final study visit. Genetic variability of Vitamin D pathway will be correlated with 25(OH)D3 serum levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage of melanoma patient</measure>
    <time_frame>study duration maximum 3,5 years</time_frame>
    <description>Vitamin D levels at diagnosis and genetic variability of the vitamin D pathway will be correlated with stage of melanoma patient at diagnosis according to the 2009 American Joint Committee of Cancer (AJCC) Melanoma staging and classification</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety endpoints:Incidence and severity of adverse events</measure>
    <time_frame>study duration maximum 3,5 years</time_frame>
    <description>Incidence and severity of adverse events will be recorded every 3 months up to final study visit.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Cutaneous Malignant Melanoma</condition>
  <arm_group>
    <arm_group_label>Vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Every month 100 000 units of Vitamin D in syringe oral dispenser is taken . Study duration is maximum 3,5 years or until relapse occurs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>arachides oleum raffinatum</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Every month 100 000 units of vitamin D in syringe Oral dispenser is taken. Study duration is maximum of 3.5 years or until relapse occurs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>prospective interventional randomized double blind placebo controlled trail&#xD;
clinical setting (tertiary university hospital)&#xD;
investigator driven, no pharmaceutical sponsor&#xD;
cutaneous malignant melanoma patients&#xD;
add- on study (placebo or vitamin D) on top of optimal standard care&#xD;
1:1 inclusion ratio (placebo:Vitamin D)&#xD;
randomisation after informed consent and screening</description>
    <arm_group_label>Vitamin D</arm_group_label>
    <other_name>D-Cure</other_name>
    <other_name>Cholecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>arachides oleum raffinatum</intervention_name>
    <arm_group_label>arachides oleum raffinatum</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Older than 18 years and younger than 80 years of age.&#xD;
&#xD;
          2. Histologically proven malignant melanoma, stage one B (IB) to three (III) Not&#xD;
             participating in other clinical trial.&#xD;
&#xD;
          3. The only treatment for melanoma is surgical treatment.&#xD;
&#xD;
          4. Complete resection of melanoma.&#xD;
&#xD;
          5. Single primary invasive cutaneous melanoma&#xD;
&#xD;
          6. Signed ethical committee approved informed consent&#xD;
&#xD;
          7. Serum phosphate, serum calcium at the entry of the study within normal limits of&#xD;
             laboratory reference&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. Pregnant/lactating women or planning on becoming pregnant during the study&#xD;
&#xD;
          2. Known hypersensitivity to vitamin D or its components.&#xD;
&#xD;
          3. Pre-existing renal stone disease, chronic renal disease with glomerular filtration&#xD;
             rate (eGFR) &lt; 30 mL/min/1.73 m2 or renal dialysis.&#xD;
&#xD;
          4. Liver failure or chronic liver disease with liver enzymes &gt; 2 fold upper limit of&#xD;
             normal (ULN).&#xD;
&#xD;
          5. History of parathyroid disease or granulomatous disease (TBC and sarcoidosis)&#xD;
&#xD;
          6. History of malabsorption syndrome or any medical condition that might interfere with&#xD;
             vitamin D absorption.&#xD;
&#xD;
          7. History of small intestine resection.&#xD;
&#xD;
          8. History of other malignancy within the last 5 years except for carcinoma in situ of&#xD;
             the cervix or basal cell carcinoma or squamous cell carcinoma of the skin or in situ&#xD;
             malignant melanoma.&#xD;
&#xD;
          9. Chronic alcohol abuse.&#xD;
&#xD;
         10. Medical or logistic problems likely to preclude completion of the study.&#xD;
&#xD;
         11. Taking medication that predisposes to hypercalcemia (digoxin, lithium, thiazide&#xD;
             diuretics) or taking medication that would affect metabolism of vitamin D&#xD;
             (anticonvulsants, corticosteroids, H2-receptor antagonists)&#xD;
&#xD;
         12. Intake of vitamin D supplements within 6 months prior to entry of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marjan Garmyn, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaire Ziekenhuizen Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marjan Garmyn, MD, PhD</last_name>
    <phone>+32 16337950</phone>
    <phone_ext>37950</phone_ext>
    <email>marjan.garmyn@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julie Desmedt, MD</last_name>
    <phone>+32 16337864</phone>
    <phone_ext>37864</phone_ext>
    <email>Julie.Desmedt@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen, Dermatology</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZLeuven Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjan Garmyn, MD PhD</last_name>
      <phone>+3216337950</phone>
      <phone_ext>37950</phone_ext>
      <email>marjan.garmyn@uzleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Julie De Smedt, MD</last_name>
      <phone>+3216337864</phone>
      <phone_ext>37864</phone_ext>
      <email>Julie.Desmedt@uzleuven.be</email>
    </contact_backup>
    <investigator>
      <last_name>Marjan Garmyn, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chef de Service du Service Universitaire de Dermatologie</name>
      <address>
        <city>Li√®ge</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dep. of Dermatology, Medical and Health Science Center University of Debrecen</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Hungary</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>December 5, 2012</study_first_submitted>
  <study_first_submitted_qc>December 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2012</study_first_posted>
  <last_update_submitted>November 4, 2020</last_update_submitted>
  <last_update_submitted_qc>November 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cutaneous malignant melanoma</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Cholecalciferol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

